This November, we’re reflecting on the incredible power of gratitude. As we honor National Family Caregivers Month, we give special thanks to caregivers everywhere—the unsung heroes who dedicate their time, energy, and hearts to supporting loved ones. ?? #NationalFamilyCaregiversMonth #Gratitude #AlzheimersAwareness
Acumen Pharmaceuticals, Inc.
生物技术研究
Greater Boston,MA 5,041 位关注者
Forging a new path towards a safe and effective treatment for Alzheimer’s disease.
关于我们
Acumen is forging a new path towards safe and effective treatments for Alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Aβo) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Aβo at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Aβo targeted drugs.
- 网站
-
https://www.acumenpharm.com
Acumen Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Greater Boston,MA
- 类型
- 上市公司
- 领域
- Alzheimer's disease、Neurodegenerative disease、therapeutics、amyloid-beta oligomers、monoclonal anitbodies和immunotherapy
地点
Acumen Pharmaceuticals, Inc.员工
动态
-
At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do! November's 'Ask Acumen' featured team member is David Potter, Director, Data Management. Click the link below to get a behind-the-scenes look at Dave's journey, passions, and outstanding contributions to our mission. Link: https://lnkd.in/gvG-tVw2 #AskAcumen #PeopleFirst #EmployeeSpotlight
-
Today we announced our Third Quarter financial results and business update. Click link to read the release??? https://lnkd.in/gPBNidrK
-
Many thanks to?NeurologyLive for featuring our Senior Clinical Research Scientist Todd Feaster, PsyD at CTAD Clinical Trials on Alzheimer's Disease 2024. Dr. Feaster discusses how the implementation of a plasma pTau217 screening assay enrichment approach is reducing unnecessary amyloid PET scans and lumbar puncture procedures in Acumen’s Phase 2 ALTITUDE-AD trial for patients with #AlzheimersDisease. He also talked about how advancements in blood-based biomarkers might shape the future of AD diagnosis. Watch the interview: https://lnkd.in/gnuynJDx #Alzheimers #ALZ #CTAD24
-
We’re searching for an Office Coordinator/Administrative Assistant to join the team at our Boston office! At Acumen, we invite our employees to bring their passion, talent, and experience to help shape our culture and enable our mission. ? Discover more about Acumen and view this opening by clicking below?? https://lnkd.in/g3VgsAsP #Recruitment #HR #Jobopportunity #Hiring #Job
-
We are thrilled to welcome Amy Schacterle, Ph.D. to the Acumen team as Chief Regulatory Officer & Head of Quality! Dr. Schacterle brings over 30 years of experience in regulatory affairs, quality assurance, and therapeutic development to Acumen. Welcome Amy! ???Click to read more: https://lnkd.in/gpzkYenv
-
Last week members of the Acumen team had the honor of attending Joy's House Adult Day Service’s 25th Anniversary “Joy of the Journey” breakfast, celebrating their remarkable milestone and kicking off 'National Caregiver Month'. This special event raised crucial funds to support the impactful programs at Joy’s House: providing a place of care and connection for individuals facing life-altering diagnoses like Alzheimer’s disease. Joy’s House holds a special place in our hearts, and we’re proud to support their mission. Thank you for your inspiring work in the Indianapolis community! #NationalCaregiverMonth #Alzheimers #AcumenCares
-
November is 'National Alzheimer's Awareness Month', a time to heighten awareness about Alzheimer's disease and show support for the more than 6.9 million Americans impacted by AD. Throughout the fall, the?Alzheimer's Association??holds their annual “Walk to End Alzheimer’s” in cities across the nation. ??This past weekend Acumen team member Mahsan Rafizadeh hit the pavement in Oahu, HI where she met?Josh Green?the governor of Hawaii who also walked to support the fight against Alzheimer's. #EndAlz?#TeamAcumen?#Alzheimersawarenessmonth?#Walk2ENDALZ
-
All good things must come to an end, and while the Acumen team is sad to leave #CTAD24, it’s been a wonderful week of sharing knowledge and innovation in the #Alzheimer’s field. We’ll see you all next year!
-
At #CTAD24 in Madrid, the Acumen team has been grateful to connect with so many of our ALTITUDE-AD study sites, partners and leaders in the Alzheimer's space. It’s been wonderful to spend time in person with so many people dedicated to AD research and innovation.